Navigation Links
Archus Orthopedics Performs First Facet Replacement Procedure With an Artificial Disc

REDMOND, Wash., Oct. 8 /PRNewswire/ -- Archus Orthopedics, Inc. today announced the first human use of its facet replacement technology to complement an artificial disc. The landmark case was performed by Dr. Karin Buttner-Janz, Dr. Hansen Yuan and Dr. Friedrich Kleinod at the Vivantes Clinic in Berlin, Germany, and involved a patient who previously underwent disc replacement surgery and later developed symptomatic facet joint degeneration. "Generally in this situation the patient is converted to spine fusion," said Dr. Karin Buttner-Janz. "With the Archus facet replacement system, we are now able to allow these patients to keep their artificial disc, retain motion, and avoid fusion," she added.

Artificial discs are implanted in patients whose natural disc has degenerated over time, resulting in chronic back pain. Historically, these patients have been treated by spine fusion surgery. Disc replacement surgery has demonstrated equivalent clinical benefit and has the added advantage of restoring normal motion to the spine. Currently, two artificial discs are approved by the Food and Drug Administration for sale in the United States, and a third disc is nearing approval. Industry analysts project rapid adoption of artificial discs once broader reimbursement is obtained.

While artificial discs represent an attractive alternative to spine fusion, they are not applicable to all patients. Many potential disc recipients are contraindicated because they also exhibit evidence of facet joint degeneration. These patients are, instead, treated by conventional spine fusion because it addresses both the disc and facet issues. In addition, since spine degeneration is often a progressive disease, some artificial disc recipients return later with degenerative facet joint problems that require revision to spine fusion. "In both scenarios, the primary issue is facet joint degeneration resulting in the need to fuse the patient, either immediately or later," said Dr. Hansen Yuan, who spearheaded development of the company's unique product family to compliment artificial discs. "Replacing the degenerative facet joint and maintaining spine motion is a much better solution than fusion," he added.

"Combining disc or nucleus replacement therapy with facet replacement expands the market for these technologies and gives surgeons all the tools they need to rebuild the entire spinal segment," said Jim Fitzsimmons, chairman and chief executive officer. "This total joint replacement approach is consistent with where things have gone in orthopedics and where they are ultimately going in spine," he added. Archus indicated that its entire family of facet replacement products has already received CE Mark approval in the European Union, where marketing trials are ongoing.

About Archus Orthopedics

Founded in July 2001, Archus Orthopedics is a privately held company developing a family of reconstructive implants to treat a variety of spine disorders resulting from degenerative changes in the facet joints. The company's first product, the Total Facet Arthroplasty System(R), has been successfully implanted in hundreds of patients worldwide, and is being evaluated in the United States in a Pivotal IDE clinical trial approved by the U.S. Food and Drug Administration. Archus has received venture capital funding from MPM Capital, InterWest Partners, Polaris Venture Partners and Johnson & Johnson Development Corporation.

SOURCE Archus Orthopedics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ascension Orthopedics Closes $21 Million Financing and Recruits an Orthopedics Industry Veteran as CEO
2. Ascension Orthopedics Launches the TITAN(TM) Humeral Resurfacing Device World Wide
3. Elsevier expands Procedures Consult with emergency medicine, orthopedics and anesthesia procedures
4. Three Industry Veterans Join Ascension Orthopedics
5. Central DuPage Hospitals Orthopedics Ranks in U.S. News Media Groups 2008 Edition of Americas Best Hospitals for the Second Consecutive Year
6. NYC-area 1st: Morgan Stanley Childrens Hospital performs transcatheter pulmonary valve replacement
7. Physician Team at Northwestern Memorial Performs Rare Oral Gallbladder Removal
8. U of M performs first systemic therapy for fatal childhood disease
9. COURAGE Sub-study: PCI Outperforms Drugs-Only
10. PET outperforms CT in characterization of lung nodules
11. ADAMS Performs Management Services for University Hospitals $600 Million Expansion/Renovation Program in Cleveland, OH
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: